Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
AI Sentiment
Highly Positive
8/10
as of 02-05-2026 3:37pm EST
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
| Founded: | 2004 | Country: | Cayman Islands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 62.0M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $12.09 | Next Earning Date: | 02-24-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -38739000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
ANL Breaking Stock News: Dive into ANL Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
AI Sentiment
Neutral
4/10
AI Sentiment
Neutral
4/10
See how ANL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ANL Adlai Nortye Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.